OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis
Helen T. Chifotides, Prithviraj Bose, Lucia Masárová, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 22, Iss. 4, pp. 210-223
Closed Access | Times Cited: 11
Helen T. Chifotides, Prithviraj Bose, Lucia Masárová, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 22, Iss. 4, pp. 210-223
Closed Access | Times Cited: 11
Showing 11 citing articles:
Momelotinib: an emerging treatment for myelofibrosis patients with anemia
Helen T. Chifotides, Prithviraj Bose, Srđan Verstovšek
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 63
Helen T. Chifotides, Prithviraj Bose, Srđan Verstovšek
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 63
Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy
Naveen Pemmaraju, Prithviraj Bose, Raajit K. Rampal, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 6, pp. 1063-1081
Open Access | Times Cited: 27
Naveen Pemmaraju, Prithviraj Bose, Raajit K. Rampal, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 6, pp. 1063-1081
Open Access | Times Cited: 27
Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
Helen T. Chifotides, Srđan Verstovšek, Prithviraj Bose
Cancers (2023) Vol. 15, Iss. 13, pp. 3331-3331
Open Access | Times Cited: 14
Helen T. Chifotides, Srđan Verstovšek, Prithviraj Bose
Cancers (2023) Vol. 15, Iss. 13, pp. 3331-3331
Open Access | Times Cited: 14
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis
Andrea Duminuco, Helen T. Chifotides, Sebastiano Giallongo, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 154-154
Open Access | Times Cited: 13
Andrea Duminuco, Helen T. Chifotides, Sebastiano Giallongo, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 154-154
Open Access | Times Cited: 13
SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis
Helen T. Chifotides, Lucia Masárová, Srđan Verstovšek
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 4, pp. 219-231
Open Access | Times Cited: 7
Helen T. Chifotides, Lucia Masárová, Srđan Verstovšek
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 4, pp. 219-231
Open Access | Times Cited: 7
Recent advances in therapies for primary myelofibrosis
William Vainchenker, Nasrine Yahmi, Violaine Havelange, et al.
Faculty Reviews (2023) Vol. 12
Open Access | Times Cited: 7
William Vainchenker, Nasrine Yahmi, Violaine Havelange, et al.
Faculty Reviews (2023) Vol. 12
Open Access | Times Cited: 7
Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what’s the current standard of care?
Mahesh Swaminathan, Akhil Jain, Sungchul Daniel Choi, et al.
Expert Review of Hematology (2024)
Closed Access | Times Cited: 1
Mahesh Swaminathan, Akhil Jain, Sungchul Daniel Choi, et al.
Expert Review of Hematology (2024)
Closed Access | Times Cited: 1
Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide
Douglas Tremblay, Ian Baine, John Mascarenhas
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 22, Iss. 12, pp. e1067-e1074
Closed Access | Times Cited: 4
Douglas Tremblay, Ian Baine, John Mascarenhas
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 22, Iss. 12, pp. e1067-e1074
Closed Access | Times Cited: 4
EXABS-164-MPN Novel Therapeutics in Development for Myelofibrosis
Helen T. Chifotides, Srđan Verstovšek
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 22, pp. S72-S74
Closed Access | Times Cited: 1
Helen T. Chifotides, Srđan Verstovšek
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 22, pp. S72-S74
Closed Access | Times Cited: 1
Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry
Joanna Góra-Tybor, Aleksandra Gołoś, Damian Mikulski, et al.
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 23, Iss. 1, pp. e19-e26
Closed Access | Times Cited: 1
Joanna Góra-Tybor, Aleksandra Gołoś, Damian Mikulski, et al.
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 23, Iss. 1, pp. e19-e26
Closed Access | Times Cited: 1
Current therapies for classic myeloproliferative neoplasms: A focus on pathophysiology and supportive care
Clement Chung
American Journal of Health-System Pharmacy (2023) Vol. 80, Iss. 22, pp. 1624-1636
Closed Access
Clement Chung
American Journal of Health-System Pharmacy (2023) Vol. 80, Iss. 22, pp. 1624-1636
Closed Access
